Plasminogen is a single chain glycoprotein zymogen which is synthesized in the liver and circulates in plasma at a concentration of approximately 2.4 µM (1,2). The plasminogen molecule contains 790 amino acids, 24 disulfide bridges, no free sulfhydryls and 5 regions of internal sequence homology, known as kringles, between Lys77 and Arg560. These five triple-looped, three disulfide bridged, kringle regions are homologous to the kringle domains in t-PA, u-PA and prothrombin. Plasminogen contains one high affinity (Kd=9x10-6M) and four low affinity (Kd=5x10-3M) lysine binding sites. The high affinity binding site resides within the first kringle region of plasminogen. The interaction of plasminogen with fibrin and α2-antiplasmin is mediated by these lysine binding sites. Native glu-plasminogen (Mr=88,000) is readily converted to Lys-77-plasminogen (Mr=83,000) by plasmin hydrolysis of the Lys76-Lys77 peptide bond. Elastase catalyzed cleavage of the Val441-Val442 peptide bond of glu-plasminogen yields a functionally active zymogen termed Val-442 plasminogen or mini-plasminogen.

The conversion of plasminogen to plasmin occurs by a variety of mechanisms, but all result in hydrolysis of the Arg560-Val561 peptide bond of plasminogen, yielding two chains which remain covalently associated by a disulfide bond.

Native glu-plasminogen is prepared from fresh frozen human plasma by a modification of the procedure of Castellino (3), utilizing gel filtration and affinity chromatography. The two carbohydrate variants of glu-plasminogen (CHOI and CHOII) are isolated by gradient elution from lysine-Sepharose using the lysine analog, e-aminocaproic acid (3). The plasminogen is supplied in 50% (vol/vol) glycerol/H2O for storage at -20oC. Purity is determined by SDS-PAGE analysis.

Haemtech生物制药服务（HBS）是一家领先的，符合cGMP要求的QC测试实验室，专门为生产重组和血浆衍生蛋白疗法的生物制药制造商提供分析服务，重点是那些会影响止血系统的药物。HBS使客户能够满足法规和质量测试要求，从而将其候选药物从开发转向商业化。

对生物制药的需求正在增长，并且该行业正在迅速采用外包策略，以作为满足不断升级的监管要求的一种方式。凭借在止血方面的丰富经验，HBS能够很好地协助开发影响凝血系统的药物产品。